TY - JOUR
T1 - Metastatic soft tissue sarcomas
T2 - A review of treatment and new pharmacotherapies
AU - Singhi, Eric K.
AU - Moore, Donald C.
AU - Muslimani, Alaa
N1 - Publisher Copyright:
© 2018, Medi Media USA Inc. All rights reserved.
PY - 2018/7
Y1 - 2018/7
N2 - Soft tissue sarcomas represent a group of heterogeneous mesenchymal tumors that occur rarely in adults. While a variety of histological subtypes exist, some of the most common are leiomyosarcoma and liposarcoma. For eligible patients, standard first-line treatment of metastatic disease has typically comprised anthracycline-containing regimens. While traditional cytotoxic chemotherapy has been the mainstay of treatment in metastatic soft tissue sarcoma, emerging targeted and novel therapies are creating new frontiers of treatment for a variety of histological subtypes. Olaratumab (Lartruvo, Eli Lilly) in combination with doxorubicin represents a new potential first-line treatment option. Second-line therapy is often histology-driven, and novel treatment options include trabectedin (Yondelis, Janssen) and eribulin (Halaven, Eisai). This review discusses the diagnosis, role of chemotherapy in unresectable and metastatic disease, and role of emerging therapies in the treatment of metastatic soft tissue sarcoma.
AB - Soft tissue sarcomas represent a group of heterogeneous mesenchymal tumors that occur rarely in adults. While a variety of histological subtypes exist, some of the most common are leiomyosarcoma and liposarcoma. For eligible patients, standard first-line treatment of metastatic disease has typically comprised anthracycline-containing regimens. While traditional cytotoxic chemotherapy has been the mainstay of treatment in metastatic soft tissue sarcoma, emerging targeted and novel therapies are creating new frontiers of treatment for a variety of histological subtypes. Olaratumab (Lartruvo, Eli Lilly) in combination with doxorubicin represents a new potential first-line treatment option. Second-line therapy is often histology-driven, and novel treatment options include trabectedin (Yondelis, Janssen) and eribulin (Halaven, Eisai). This review discusses the diagnosis, role of chemotherapy in unresectable and metastatic disease, and role of emerging therapies in the treatment of metastatic soft tissue sarcoma.
UR - http://www.scopus.com/inward/record.url?scp=85049672868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049672868&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:85049672868
SN - 1052-1372
VL - 43
SP - 410-415, 429
JO - P and T
JF - P and T
IS - 7
ER -